Royall P G, Craig D Q, Doherty C
Centre for Materials Science, The School of Pharmacy, University of London, UK.
Pharm Res. 1998 Jul;15(7):1117-21. doi: 10.1023/a:1011902816175.
The use of modulated differential scanning calorimetry (MDSC) as a novel means of characterising the glass transition of amorphous drugs has been investigated, using the protease inhibitor saquinavir as a model compound. In particular, the effects of measuring variables (temperature cycling, scanning period, heating mode) have been examined.
Saquinavir samples of known moisture content were examined using a TA Instruments 2920 MDSC at a heating rate of 2 degrees C/min and an amplitude of +/-0.159 degrees C with a period of 30 seconds. These conditions were used to examine the effects of cycling between - 50 degrees C and 150 degrees C. A range of periods between 20 and 50 seconds were then studied. Isothermal measurements were carried out between 85 degrees C and 120 degrees C using an amplitude of +/-0.159 degrees C with a period of 30 seconds.
MDSC showed the glass transition of saquinavir (0.98 +/- 0.05%w/w moisture content) in isolation from the relaxation endotherm to give an apparent glass transition temperature of 107.0 degrees C +/- 0.4 degrees C. Subsequent temperature cycling gave reproducible glass transition temperatures of approximately 105 degrees C for both cooling and heating cycles. The enthalpic relaxation peak observed in the initial heating cycle had an additional contribution from a Tg "shift" effect brought about by the difference in response to the glass transition of the total and reversing heat flow signals. Isothermal studies yield a glass transition at 105.9 degrees C +/- 0.1 degrees C.
MDSC has been shown to be capable of separating the glass transition of saquinavir from the relaxation endotherm, thereby facilitating measurement of this parameter without the need for temperature cycling. However, the Tg "shift" effect and the number of modulations through the transition should be taken into account to avoid drawing erroneous conclusions from the experimental data. MDSC has been shown to be an effective method of characterising the glass transition of an amorphous drug, allowing the separate characterisation of the Tg and endothermic relaxation in the first heating cycle.
以蛋白酶抑制剂沙奎那韦作为模型化合物,研究了调制式差示扫描量热法(MDSC)作为表征无定形药物玻璃化转变的新方法。特别考察了测量变量(温度循环、扫描周期、加热模式)的影响。
使用TA Instruments 2920 MDSC对已知水分含量的沙奎那韦样品进行检测,加热速率为2℃/分钟,振幅为±0.159℃,周期为30秒。这些条件用于考察在-50℃至150℃之间循环的影响。随后研究了20至50秒范围内的一系列周期。在85℃至120℃之间进行等温测量,振幅为±0.159℃,周期为30秒。
MDSC显示,水分含量为0.98±0.05%(w/w)的沙奎那韦的玻璃化转变与弛豫吸热峰分离,表观玻璃化转变温度为107.0℃±0.4℃。随后的温度循环给出了冷却和加热循环中约105℃的可重现玻璃化转变温度。在初始加热循环中观察到的焓松弛峰,由于总热流信号和反向热流信号对玻璃化转变的响应差异导致的Tg“偏移”效应,有额外的贡献。等温研究得出玻璃化转变温度为105.9℃±0.1℃。
已证明MDSC能够将沙奎那韦的玻璃化转变与弛豫吸热峰分离,从而无需温度循环即可方便地测量该参数。然而,应考虑Tg“偏移”效应和通过转变的调制次数,以避免从实验数据得出错误结论。已证明MDSC是表征无定形药物玻璃化转变的有效方法,能够在第一个加热循环中分别表征Tg和吸热弛豫。